How to Starve Cancer

Product Information

To her doctor’s utter amazement, it appeared that McLelland had beaten the odds once again. Nine months later, she was not only alive, but her cancer blood markers were good.

Today I have an interview with my friend and 15-year holistic terminal cancer survivor Jane McLelland, author of How to Starve Cancer. McLelland discovered that there were numerous drugs on the market designed for other purposes (like heart disease or infections) that could go beyond diet and supplements to effectively cut off cancer’s various fuel lines. These drugs are considered “off-label,” since they were developed for conditions other than cancer. I do believe we already have every drug and every supplement that we need to beat cancer. The key is getting the right combinations to people at the right time,” said McLelland. “Yes, in certain circumstances there can be too much damage to the body from the cancer itself. But if you can get to people before that, I cannot see why patients can’t be rescued even from advanced malignancies. Stage IV cancer should not be a death sentence, in my view.” What made the diagnosis even more tragic was the fact that McLelland’s doctor had misdiagnosed her for years. Since cervical cancer is highly treatable in its early stages, her tragedy could have been avoided. Cancer cells typically proliferate from one aberrant cell to more than 10 9cells (the average number of cells in a tumor of ∼1 cm in diameter). To achieve and sustain that proliferative capacity, cancer cells must activate or enhance metabolic pathways ( Lunt and Vander Heiden, 2011). These pathways use available nutrients to… to satisfy the energy demand for cell maintenance…This studysays the recent surge of interest in understanding cancer metabolism has identified several alternative fuels that tumor cells can utilize to support their metabolic needs. The dependence of tumors on these fuels reveals their unexpected metabolic flexibility to utilize a wide variety of alternative fuels. Just like the cervical cancer, Jane’s lung cancer was initially misdiagnosed (this time as a chest infection). But the benefit of having the improperly read X-ray from four months prior—along with the properly diagnosed X-ray—was the ability to see the rate at which the cancer was growing.

For people currently struggling with a cancer diagnosis, McLelland has an important message: Never give up. In the early stages of her research, McLelland first learned that glucose feeds most cancers and that IGF-1 (an insulin-like growth factor hormone found in high levels in dairy and meat) also helped to drive its growth. Since her remarkable recovery, Jane has been a staunch supporter of ‘off label’ drugs for cancer therapy (medicines used for other conditions than their approved licence). McLelland created a diagram depicting her approach to starving cancer that she calls the “Metro Map,” based on an analogy of an underground metro system.

Jane is winner of the Lifetime Achievement Award 2019 ‘Amazing Women Global’ for unsung heroines. Awarded for Jane’s work educating and helping cancer patients since 2003. Years later, she also discovered the anti-cancer effects of the antibiotic doxycycline (which slows the creation of new cancer cells) and of the anti-worming drug mebendazole (which stops the cancer cells from being able to take on more glucose). Another key, off-label drug McLelland learned about from reading Life Extension was the diabetes drug, metformin. Metformin is critical for starving cancer because it cuts off cancer’s supply to glucose and insulin, and reduces IGF-1.

Jane was diagnosed with cervical cancer in 1994 and did conventional treatment. In 1999 her cancer progressed to stage IV and she started incorporating complementary and alternative treatments alongside chemotherapy. In 2004 she started developing leukemia as a result of the chemotherapy and/or radiotherapy treatments she received.In this truly ground-breaking book, Jane takes us through her remarkable, heart-breaking journey, and the medical discoveries she made along the way. The use of ‘off label’ drugs for treating cancer is finally gaining traction. Yet Jane discovered these herself in 2003. Unbeknown to her, she would become ‘patient zero’. McLelland’s cervical cancer markers were in the normal range. But in 2003, she received yet another death sentence: treatment-related myelodysplasia, a form of bone marrow mutation that may progress to leukemia. You have done a magnificent job in your course… you are providing more relevant information for patients than any other integrative medicine source or platform. You are establishing a way forward that is bringing truly relevant information for people diagnosed with cancer-and their families-and their physicians.

It will teach you everything you need to know about cancer metabolism, no matter what type or stage of cancer you have. Here’s what other people have said about the course: Use short term. Concurrent use of a statin and Dipyridamole mitigates cardio effects and enhances efficacy. This book will answer all the burning questions you face when you begin to explore integrative treatments. Which ‘off-label’ drugs and supplements should you take? Should you try the ketogenic diet? Should you fast? Is fat safe? How much and when should you exercise? Jane explains why each patient needs a personalised approach and, importantly, how to work this out. Using protocols similar to those used by Jane McLelland, The Care Oncology Clinic (a leading London cancer clinic) is undertaking a study and providing treatments that include off-label drugs. All of these drugs are cheap and off-patent, which is why they have largely been ignored by the pharmaceutical industry, despite research supporting their effectiveness against cancer,” said McLelland.Now, 18 years after her initial cancer diagnosis—after battling cervical, lung, and blood cancers—McLelland is living the life of her dreams. She married the love of her life, and through the selflessness of a surrogate, was able to have two sons of her own. However, McLelland cautions that there is no one-size-fits-all approach. Her own experience with her various forms of cancer highlight that fact. Instead, McLelland’s approach focuses on learning which fuel sources your particular cancer uses—and then creating a targeted treatment plan based on that information. McLelland believed she had finally found out how to beat her cancer once and for all. And her test results proved her right. Blood tests revealed that her TM2PK tumor markers (a marker of abnormal glycolysis) had dropped from 397 to 21.5—just slightly above a “normal” reading of 15. But McLelland refused to go down without a fight. Taking matters into her own hands, she dug through medical journals, poring over long-forgotten research and overlooked evidence, looking for clues to overcoming her cancer.